8-K current report · filed Nov 4, 2026

Edwards Lifesciences (EW) 8-K Current Report: November 4, 2026

Item 2.02Item EX-99.1EW overview

Short answer

Edwards Lifesciences (EW) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Edwards issued third-quarter 2026 financial results on November 4, 2026.

Edwards Lifesciences 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Edwards issued third-quarter 2026 financial results on November 4, 2026
  • Investor-relevant figures and management commentary are contained in Exhibit 99.1, the accompanying earnings release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 sales $1.72B, up 10.5%, with adjusted EPS $0.80, up 19% year over year
  • TAVR sales $1.24B, up 8.0%, supporting continued leadership in Edwards’ core structural-heart franchise
  • TMTT sales $207M, up 44.0%, the key growth engine as PASCAL and EVOQUE adoption accelerates
  • 2026 guidance raised: sales growth approximately 11.5%, TAVR growth 9.0% to 9.5%, adjusted EPS $2.97 to $3.05
  • Q3 included a $220.2M impairment charge, leaving GAAP operating margin 17.4% versus 30.3% adjusted

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Edwards Lifesciences 8-K filings

Get the next EW 8-K as it lands

Follow EW for push alerts, or ask the research agent what this filing means.